Latest oppositions filed by Ethypharm

This table presents recent patent oppositions filed by Ethypharm against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3578173Dosage Form Containing Oxycodone And NaloxoneEURO-CELTIQUE S.A.Jul 26, 2023
EP3345602Rapamycin Derivative For Treating Advanced Solid TumoursNOVARTIS AGJan 6, 2023
EP3391890Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-CyclodextrinMERCK SHARP & DOHME CORP.May 25, 2022
EP3342411Rapamycin Derivative For Treating Pancreas CancerNOVARTIS AGFeb 14, 2020
EP2962686Dosage Form Containing Oxycodone And NaloxoneEURO-CELTIQUE S.A.Jan 9, 2020
EP3351246Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTIS AGJul 3, 2019
EP3143995A Rapamycin Derivative For Treating Lung CancerNOVARTIS AGJun 12, 2019
EP2762140Treatment Of Solid Brain Tumours With A Rapamycin DerivativeNOVARTIS AGDec 22, 2017
EP2425821Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO-CELTIQUE S.A.Nov 7, 2017
EP2425824Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO-CELTIQUE S.A.Nov 7, 2017

The following table provides an overview of the latest patents of Ethypharm that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3115041Oct 25, 2023Crush-Resistant Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion2